Tend Health Inc. – Clinical Study for Tend’s Gut Microbiome Collection and Prep (CAP) Device in Clostridium difficile Infection
Thomas Lendvay, CMO and co-founder of Tend Health, Inc. discusses the recent announcement of the initiation of a clinical trial at Massachusetts General Hospital evaluating the comparability of the company’s Gut Microbiome CAP device to current non-standardized methodologies for the delivery of Fecal Microbiota Transplant (FMT) for patients suffering from Clostridium difficile infection.
Dr. Lendvay is a surgeon and entrepreneur. He is currently on leave from his position as a Professor in the Department of Urology at the University of Washington and co-Director of Seattle Children’s Robotic Surgery Center, as he focuses on Tend. Dr. Lendvay was the co-founder and Chief Medical Officer of CSATS (acquired by Johnson & Johnson in 2018). His research and innovation focus on disruptive technologies to improve patient outcomes.
